Senseonics Holdings, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sean Lee CFA from H.C. Wainwright reiterated a Buy rating on the stock and has a $1.40 price target.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sean Lee CFA has given his Buy rating due to a combination of factors that indicate strong growth potential for Senseonics Holdings. The company has outlined an ambitious plan to significantly increase its patient base for the Eversense system, aiming to grow from 13,000 patients in 2025 to over 50,000 by 2027. This growth is supported by several strategic initiatives, including the anticipated approval and launch of Eversense 365 in the EU and its pairing with Sequel Diabetes’ twiist insulin delivery system, both expected in the second half of 2025.
Additionally, the introduction of the Gemini and Freedom systems in the following years is expected to further drive revenue growth. The company’s updated financial projections reflect these developments, with expected revenues rising to $75.6 million in 2026 and $118.4 million in 2027. These factors, along with the potential for operational break-even by the end of 2027, have led to an increased 12-month price target of $1.40 per share, reinforcing the Buy recommendation.